Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages post-meal glucose spikes when taken right before meals. Hypoglycemia risk increases if meals are delayed, skipped, or low in carbohydrates. Suitable for elderly patients and those with severe sulfur or sulfonylurea allergies, it can be used alone or combined with biguanides.

Repaglinide is absorbed rapidly, reaching peak blood levels within an hour, making it suitable for pre-meal usage. It's mainly metabolized by the liver, with a small amount processed by the kidneys, necessitating caution in patients with renal insufficiency. Its major side effect is hypoglycemia, and its effectiveness can decline after initial improvements. Some drugs may enhance its action by altering its metabolism or displacing it from plasma protein-binding sites.

Nateglinide promotes insulin secretion swiftly but less enduringly than other oral antidiabetic agents. It effectively reduces post-meal glycemic spikes when taken shortly before meals. Metabolized primarily by hepatic CYPs, it should be used cautiously in patients with liver insufficiency. Certain drugs may reduce the glucose-lowering effect of nateglinide or increase the risk of hypoglycemia. Unlike other insulin secretagogues, nateglinide may lead to fewer hypoglycemic episodes but has similar secondary failure rates.

Dal capitolo 25:

article

Now Playing

25.12 : Oral Hypoglycemic Agents: Glinides

Insulin and Hypoglycemic Drugs

56 Visualizzazioni

article

25.1 : Omeostasi del glucosio: regolazione della glicemia

Insulin and Hypoglycemic Drugs

842 Visualizzazioni

article

25.2 : Omeostasi del glucosio: isole pancreatiche e secrezione di insulina

Insulin and Hypoglycemic Drugs

650 Visualizzazioni

article

25.3 : Insulina: il recettore e le vie di segnalazione

Insulin and Hypoglycemic Drugs

704 Visualizzazioni

article

25.4 : Fisiopatologia del diabete

Insulin and Hypoglycemic Drugs

501 Visualizzazioni

article

25.5 : Diabete: sintomi, diagnosi e complicanze

Insulin and Hypoglycemic Drugs

360 Visualizzazioni

article

25.6 : Diabete: gestione e farmacoterapia

Insulin and Hypoglycemic Drugs

138 Visualizzazioni

article

25.7 : Insulina: biosintesi, chimica e preparazione

Insulin and Hypoglycemic Drugs

160 Visualizzazioni

article

25.8 : Formulazioni di insulina: tipi e somministrazione

Insulin and Hypoglycemic Drugs

76 Visualizzazioni

article

25.9 : Insulina: regime di dosaggio ed effetti avversi

Insulin and Hypoglycemic Drugs

63 Visualizzazioni

article

25.10 : Ipoglicemizzanti orali: Sulfoniluree

Insulin and Hypoglycemic Drugs

74 Visualizzazioni

article

25.11 : Ipoglicemizzanti orali: biguanidi e glitazoni

Insulin and Hypoglycemic Drugs

79 Visualizzazioni

article

25.13 : Ipoglicemizzanti orali: inibitori della α-glucosidasi

Insulin and Hypoglycemic Drugs

60 Visualizzazioni

article

25.14 : Agonisti del recettore glucagone-simile

Insulin and Hypoglycemic Drugs

113 Visualizzazioni

article

25.15 : Inibitori della dipeptidil peptidasi 4

Insulin and Hypoglycemic Drugs

55 Visualizzazioni

See More

JoVE Logo

Riservatezza

Condizioni di utilizzo

Politiche

Ricerca

Didattica

CHI SIAMO

Copyright © 2025 MyJoVE Corporation. Tutti i diritti riservati